Malaria continues to exact a great human toll in tropical settings. Antimalarial resistance is rife and the parasite inexorably develops mechanisms to outwit our best drugs, including the now first-line choice, artesunate. Novel strategies to circumvent resistance are needed. Here we detail drug development focusing on heat shock protein 90 and its central role as a chaperone. A growing body of evidence supports the role for Hsp90 inhibitors as adjunctive drugs able to restore susceptibility to traditionally efficacious compounds like chloroquine.
References
[1]
Sachs, J.; Malaney, P. The economic and social burden of malaria. Nature 2002, 415, 680–685, doi:10.1038/415680a.
[2]
Snow, R.W.; Guerra, C.A.; Noor, A.M.; Myint, H.Y.; Hay, S.I. The global distribution of clinical episodes of plasmodium falciparum malaria. Nature 2005, 434, 214–217.
[3]
Hay, S.I.; Guerra, C.A.; Tatem, A.J.; Noor, A.M.; Snow, R.W. The global distribution and population at risk of malaria: Past, present, and future. Lancet Infect. Dis. 2004, 4, 327–336.
[4]
Acharya, P.; Kumar, R.; Tatu, U. Chaperoning a cellular upheaval in malaria: Heat shock proteins in plasmodium falciparum. Mol. Biochem. Parasitol. 2007, 153, 85–94, doi:10.1016/j.molbiopara.2007.01.009.
[5]
Sherman, I.W. The life of plasmodium: An overview. In Molecular approaches to malaria; Sherman, I.W., Ed.; ASM Press: Washington, D.C., USA, 2005; pp. 3–23.
[6]
Zak, O.; Carbon, C.; Fantin, B.; Kaminsky, R. Malaria. In Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy; Sande, M.A., O'Reilly, T., Eds.; Academic Press: London, UK, 1999; pp. 757–773.
[7]
Ashley, E.; McGready, R.; Singhasivanon, P.; Nosten, F.; Carrara, V.; Price, R. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in thailand in 2003. Trop. Med. Int. Health 2006, 11, 1898–1899, doi:10.1111/j.1365-3156.2006.01749_1.x.
[8]
Ndam, N.T.; Deloron, P. Molecular aspects of plasmodium falciparum infection during pregnancy. J. Biomed. Biotech. 2007, 2007, 43785.
[9]
Douradinha, B.; Doolan, D.L. Harnessing immune responses against plasmodium for rational vaccine design. Trends Para. 2011, 27, 274–283, doi:10.1016/j.pt.2011.01.002.
Alonso, P.L.; Sacarlal, J.; Aponte, J.J.; Leach, A.; Macete, E.; Milman, J.; Mandomando, I.; Spiessens, B.; Guinovart, C.; Espasa, M.; et al. Efficacy of the rts,s/as02a vaccine against plasmodium falciparum infection and disease in young african children: Randomised controlled trial. Lancet 2004, 364, 1411–1420.
[14]
Alonso, P.L.; Sacarlal, J.; Aponte, J.J.; Leach, A.; Macete, E.; Aide, P.; Sigauque, B.; Milman, J.; Mandomando, I.; Bassat, Q.; et al. Duration of protection with rts,s/as02a malaria vaccine in prevention of plasmodium falciparum disease in mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 2005, 366, 2012–2018.
[15]
Bejon, P.; Lusingu, J.; Olotu, A.; Leach, A.; Lievens, M.; Vekemans, J.; Mshamu, S.; Lang, T.; Gould, J.; Dubois, M.C.; et al. Efficacy of rts,s/as01e vaccine against malaria in children 5 to 17 months of age. New Eng. J. Med. 2008, 359, 2521–2532.
[16]
Fidock, D.A.; Rosenthal, P.J.; Croft, S.L.; Brun, R.; Nwaka, S. Antimalarial drug discovery: Efficacy models for compound screening. Nat Rev. Drug Disc. 2004, 3, 509–520.
[17]
Peters, W.; Robinson, B.L.; Ellis, D.S. The chemotherapy of rodent malaria. Xlii. Halofantrine and halofantrine resistance. Ann. Trop. Med. Para. 1987, 81, 639–646.
[18]
Tuteja, R. Malaria - an overview. FEBS 2007, 274, 4670–4679.
[19]
Cowman, A.F.; Crabb, B.S. Invasion of red blood cells by malaria parasites. Cell 2006, 124, 755–766, doi:10.1016/j.cell.2006.02.006.
[20]
Bray, R.S.; Garnham, P.C. The life-cycle of primate malaria parasites. Brit. Med. Bull. 1982, 38, 117–122.
[21]
Chin, W.; Contacos, P.G.; Coatney, G.R.; Kimball, H.R. A naturally acquited quotidian-type malaria in man transferable to monkeys. Science 1965, 149, 865.
[22]
Bannister, L.; Mitchell, G. The ins, outs and roundabouts of malaria. Trends Para. 2003, 19, 209–213.
[23]
Baumeister, S.; Winterberg, M.; Przyborski, J.M.; Lingelbach, K. The malaria parasite plasmodium falciparum: Cell biological peculiarities and nutritional consequences. Protoplasma 2010, 240, 3–12, doi:10.1007/s00709-009-0090-3.
Cooke, B.M.; Mohandas, N.; Coppel, R.L. Malaria and the red blood cell membrane. Sem. Hematol. 2004, 41, 173–188.
[27]
Ben Mamoun, C.; Gluzman, I.Y.; Hott, C.; MacMillan, S.K.; Amarakone, A.S.; Anderson, D.L.; Carlton, J.M.; Dame, J.B.; Chakrabarti, D.; Martin, R.K.; et al. Co-ordinated programme of gene expression during asexual intraerythrocytic development of the human malaria parasite plasmodium falciparum revealed by microarray analysis. Mol. Micro. 2001, 39, 26–36, doi:10.1046/j.1365-2958.2001.02222.x.
[28]
Koussis, K.; Withers-Martinez, C.; Yeoh, S.; Child, M.; Hackett, F.; Knuepfer, E.; Juliano, L.; Woehlbier, U.; Bujard, H.; Blackman, M.J. A multifunctional serine protease primes the malaria parasite for red blood cell invasion. EMBO 2009, 28, 725–735, doi:10.1038/emboj.2009.22.
[29]
Fidock, D.A. Drug discovery: Priming the antimalarial pipeline. Nature 2010, 465, 297–298, doi:10.1038/465297a.
[30]
Gregson, A.; Plowe, C.V. Mechanisms of resistance of malaria parasites to antifolates. Pharm. Rev. 2005, 57, 117–145, doi:10.1124/pr.57.1.4.
[31]
Taylor, D.K.; Avery, T.D.; Greatrex, B.W.; Tiekink, E.R.; Macreadie, I.G.; Macreadie, P.I.; Humphries, A.D.; Kalkanidis, M.; Fox, E.N.; Klonis, N.; et al. Novel endoperoxide antimalarials: Synthesis, heme binding, and antimalarial activity. J. Med. Chem. 2004, 47, 1833–1839, doi:10.1021/jm0305319.
[32]
Imwong, M.; Pukrittakayamee, S.; Looareesuwan, S.; Pasvol, G.; Poirreiz, J.; White, N.J.; Snounou, G. Association of genetic mutations in plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: Geographical and clinical correlates. Antimicrob. Agents Chemother. 2001, 45, 3122–3127, doi:10.1128/AAC.45.11.3122-3127.2001.
Krogstad, D.J.; Gluzman, I.Y.; Kyle, D.E.; Oduola, A.M.; Martin, S.K.; Milhous, W.K.; Schlesinger, P.H. Efflux of chloroquine from plasmodium falciparum: Mechanism of chloroquine resistance. Science 1987, 238, 1283–1285.
[35]
Wellems, T.E.; Walker-Jonah, A.; Panton, L.J. Genetic mapping of the chloroquine-resistance locus on plasmodium falciparum chromosome 7. Proc. Nat. Acad. Sci. USA 1991, 88, 3382–3386, doi:10.1073/pnas.88.8.3382.
[36]
Djimde, A.; Doumbo, O.K.; Steketee, R.W.; Plowe, C.V. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001, 358, 890–891.
[37]
Djimde, A.; Doumbo, O.K.; Cortese, J.F.; Kayentao, K.; Doumbo, S.; Diourte, Y.; Dicko, A.; Su, X.Z.; Nomura, T.; Fidock, D.A.; et al. A molecular marker for chloroquine-resistant falciparum malaria. New Eng. J. Med. 2001, 344, 257–263.
[38]
Eckstein-Ludwig, U.; Webb, R.J.; Van Goethem, I.D.; East, J.M.; Lee, A.G.; Kimura, M.; O'Neill, P.M.; Bray, P.G.; Ward, S.A.; Krishna, S. Artemisinins target the serca of plasmodium falciparum. Nature 2003, 424, 957–961.
[39]
Uhlemann, A.C.; Krishna, S. Antimalarial multi-drug resistance in asia: Mechanisms and assessment. Curr. Topics Micro. Immunol. 2005, 295, 39–53, doi:10.1007/3-540-29088-5_2.
[40]
White, N.J. Preventing antimalarial drug resistance through combinations. Drug Res. Updates 1998, 1, 3–9, doi:10.1016/S1368-7646(98)80208-2.
Pereira, M.R.; Henrich, P.P.; Sidhu, A.B.; Johnson, D.; Hardink, J.; Van Deusen, J.; Lin, J.; Gore, K.; O'Brien, C.; Wele, M.; et al. In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. Antimicrob. Agents Chemother. 2011, 55, 3115–3124.
[43]
Pesce, E.R.; Cockburn, I.L.; Goble, J.L.; Stephens, L.L.; Blatch, G.L. Malaria heat shock proteins: Drug targets that chaperone other drug targets. Infect. Dis. Drug Tartgets 2010, 10, 147–157.
[44]
Shonhai, A. Plasmodial heat shock proteins: Targets for chemotherapy. FEMS Immunol. Med. Micro. 2010, 58, 61–74, doi:10.1111/j.1574-695X.2009.00639.x.
[45]
Wegele, H.; Muller, L.; Buchner, J. Hsp70 and hsp90--a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 2004, 151, 1–44, doi:10.1007/s10254-003-0021-1.
[46]
Smith, D.F.; Sullivan, W.P.; Marion, T.N.; Zaitsu, K.; Madden, B.; McCormick, D.J.; Toft, D.O. Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70. Mol. Cell. Biol. 1993, 13, 869–876.
[47]
Cowen, L.E.; Lindquist, S. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 2005, 309, 2185–2189.
[48]
Cowen, L.E.; Singh, S.D.; Kohler, J.R.; Collins, C.; Zaas, A.K.; Schell, W.A.; Aziz, H.; Mylonakis, E.; Perfect, J.R.; Whitesell, L.; et al. Harnessing hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Nat. Acad. Sci. USA 2009, 106, 2818–2823.
[49]
Marubayashi, S.; Koppikar, P.; Taldone, T.; Abdel-Wahab, O.; West, N.; Bhagwat, N.; Caldas-Lopes, E.; Ross, K.N.; Gonen, M.; Gozman, A.; et al. Hsp90 is a therapeutic target in jak2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 2010, 120, 3578–3593.
[50]
Mollapour, M.; Neckers, L. Post-translational modifications of hsp90 and their contributions to chaperone regulation. Biochim. Biophys. Acta 2011, 1823, 648–655, doi:10.1016/j.bbamcr.2011.07.018.
Tatokoro, M.; Koga, F.; Yoshida, S.; Kawakami, S.; Fujii, Y.; Neckers, L.; Kihara, K. Potential role of hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int. J. Cancer 2011, 131, 987–996.
[53]
Wang, Y.; Trepel, J.B.; Neckers, L.M.; Giaccone, G. Sta-9090, a small-molecule hsp90 inhibitor for the potential treatment of cancer. Curr. Opin. Invest. Drugs 2010, 11, 1466–1476.
[54]
Cowen, L.E.; Carpenter, A.E.; Matangkasombut, O.; Fink, G.R.; Lindquist, S. Genetic architecture of hsp90-dependent drug resistance. Euk. Cell 2006, 5, 2184–2188, doi:10.1128/EC.00274-06.
[55]
Pavithra, S.R.; Kumar, R.; Tatu, U. Systems analysis of chaperone networks in the malarial parasite plasmodium falciparum. PLoS Comp. Bio. 2007, 3, 1701–1715.
[56]
Cerchietti, L.C.; Hatzi, K.; Caldas-Lopes, E.; Yang, S.N.; Figueroa, M.E.; Morin, R.D.; Hirst, M.; Mendez, L.; Shaknovich, R.; Cole, P.A.; et al. Bcl6 repression of ep300 in human diffuse large b cell lymphoma cells provides a basis for rational combinatorial therapy. J. Clin. Invest. 2010, doi:10.1172/JCI42869.
[57]
Taldone, T.; Gillan, V.; Sun, W.; Rodina, A.; Patel, P.; Maitland, K.; O'Neill, K.; Chiosis, G.; Devaney, E. Assay strategies for the discovery and validation of therapeutics targeting brugia pahangi hsp90. PLoS Neg. Trop. Dis. 2010, 4, e714.
[58]
Taldone, T.; Gomes-DaGama, E.M.; Zong, H.; Sen, S.; Alpaugh, M.L.; Zatorska, D.; Alonso-Sabadell, R.; Guzman, M.L.; Chiosis, G. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. Bio. Med. Chem. Let. 2011, 21, 5347–5352, doi:10.1016/j.bmcl.2011.07.026.
[59]
Taldone, T.; Zatorska, D.; Patel, P.D.; Zong, H.; Rodina, A.; Ahn, J.H.; Moulick, K.; Guzman, M.L.; Chiosis, G. Design, synthesis, and evaluation of small molecule hsp90 probes. Bioorg. Med. Chem. 2011, 19, 2603–2614, doi:10.1016/j.bmc.2011.03.013.
[60]
Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (hsp90) inhibitors in cancers. Biochim. Biophys. Acta 2011, 1823, 742–755.
[61]
Usmani, S.Z.; Chiosis, G. Hsp90 inhibitors as therapy for multiple myeloma. Clin. Lymp. Myel. Leuk. 2011, 11 (Suppl. 1), S77–S81, doi:10.1016/j.clml.2011.03.027.
[62]
Banumathy, G.; Singh, V.; Pavithra, S.R.; Tatu, U. Heat shock protein 90 function is essential for plasmodium falciparum growth in human erythrocytes. J. Biol. Chem. 2003, 278, 18336–18345.
[63]
Kumar, R.; Pavithra, S.R.; Tatu, U. Three-dimensional structure of heat shock protein 90 from plasmodium falciparum: Molecular modelling approach to rational drug design against malaria. J. Biosc. 2007, 32, 531–536.
[64]
Pallavi, R.; Roy, N.; Nageshan, R.K.; Talukdar, P.; Pavithra, S.R.; Reddy, R.; Venketesh, S.; Kumar, R.; Gupta, A.K.; Singh, R.K.; et al. Heat shock protein 90 as a drug target against protozoan infections: Biochemical characterization of hsp90 from plasmodium falciparum and trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J. Biol. Chem. 2010, 285, 37964–37975.
[65]
Pavithra, S.R.; Banumathy, G.; Joy, O.; Singh, V.; Tatu, U. Recurrent fever promotes plasmodium falciparum development in human erythrocytes. J. Biol. Chem. 2004, 279, 46692–46699.
[66]
Dutta, R.; Inouye, M. Ghkl, an emergent atpase/kinase superfamily. Trends Biochem. Sci. 2000, 25, 24–28.
[67]
Singh, S.D.; Robbins, N.; Zaas, A.K.; Schell, W.A.; Perfect, J.R.; Cowen, L.E. Hsp90 governs echinocandin resistance in the pathogenic yeast candida albicans via calcineurin. PLoS Path. 2009, 5, e1000532, doi:10.1371/journal.ppat.1000532.
[68]
Dollins, D.E.; Immormino, R.M.; Gewirth, D.T. Structure of unliganded grp94, the endoplasmic reticulum hsp90. Basis for nucleotide-induced conformational change. J. Biol. Chem. 2005, 280, 30438–30447, doi:10.1074/jbc.M503761200.
[69]
Dollins, D.E.; Warren, J.J.; Immormino, R.M.; Gewirth, D.T. Structures of grp94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell 2007, 28, 41–56.
[70]
Immormino, R.M.; Dollins, D.E.; Shaffer, P.L.; Soldano, K.L.; Walker, M.A.; Gewirth, D.T. Ligand-induced conformational shift in the n-terminal domain of grp94, an hsp90 chaperone. J. Bio. Chem. 2004, 279, 46162–46171.
[71]
Immormino, R.M.; Metzger, L.E.t.; Reardon, P.N.; Dollins, D.E.; Blagg, B.S.; Gewirth, D.T. Different poses for ligand and chaperone in inhibitor-bound hsp90 and grp94: Implications for paralog-specific drug design. J. Mol. Bio. 2009, 388, 1033–1042.
[72]
Johnson, J.L.; Brown, C. Plasticity of the hsp90 chaperone machine in divergent eukaryotic organisms. Cell Stress Chap. 2009, 14, 83–94, doi:10.1007/s12192-008-0058-9.
[73]
Shonhai, A.; Maier, A.G.; Przyborski, J.M.; Blatch, G.L. Intracellular protozoan parasites of humans: The role of molecular chaperones in development and pathogenesis. Pro. Pep. Lett. 2011, 18, 143–157, doi:10.2174/092986611794475002.
[74]
Gitau, G.W.; Mandal, P.; Blatch, G.L.; Przyborski, J.; Shonhai, A. Characterisation of the plasmodium falciparum hsp70-hsp90 organising protein (pfhop). Cell Stress Chap. 2012, 17, 191–202.
[75]
Chiosis, G.; Caldas Lopes, E.; Solit, D. Heat shock protein-90 inhibitors: A chronicle from geldanamycin to today's agents. Curr. Opin. Invest. Drugs 2006, 7, 534–541.
[76]
Whitesell, L.; Mimnaugh, E.G.; De Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc. Nat. Acad. Sci. USA 1994, 91, 8324–8328, doi:10.1073/pnas.91.18.8324.
[77]
Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Hsp90: The vulnerable chaperone. Drug Disc. Today 2004, 9, 881–888, doi:10.1016/S1359-6446(04)03245-3.
[78]
Taldone, T.; Gillan, V.; Sun, W.; Rodina, A.; Patel, P.; Maitland, K.; O'Neill, K.; Chiosis, G.; Devaney, E. Assay strategies for the discovery and validation of therapeutics targeting brugia pahangi hsp90. PLoS Negl. Trop. Dis. 2010, 4, e714.
[79]
Elo, M.A.; Kaarniranta, K.; Helminen, H.J.; Lammi, M.J. Hsp90 inhibitor geldanamycin increases hsp70 mrna stabilisation but fails to activate hsf1 in cells exposed to hydrostatic pressure. Biochim. Biophys. Acta 2005, 1743, 115–119, doi:10.1016/j.bbamcr.2004.09.004.
Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting hsp90: Small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 2008, 8, 370–374, doi:10.1016/j.coph.2008.06.015.
[82]
Caldas-Lopes, E.; Cerchietti, L.; Ahn, J.H.; Clement, C.C.; Robles, A.I.; Rodina, A.; Moulick, K.; Taldone, T.; Gozman, A.; Guo, Y.; et al. Hsp90 inhibitor pu-h71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA 2009, 106, 8368–8373.
[83]
Krause, S.; Willighagen, E.; Steinbeck, C. Jchempaint: Using the collaborative forces of the internet to develop a free editor for 2d chemical structures. Molecules 2000, 5, 93–98, doi:10.3390/50100093.
[84]
Su, X.Z.; Wellems, T.E. Sequence, transcript characterization and polymorphisms of a plasmodium falciparum gene belonging to the heat-shock protein (hsp) 90 family. Gene 1994, 151, 225–230, doi:10.1016/0378-1119(94)90661-0.
[85]
Banumathy, G. Functional insights into heat shock protein 90 multichaperone complex in plasmodium falciparum. A Thesis submitted for the Degree of Doctor, Philosophy in the Faculty of Science, Department of Biochemistry, Bangalore University, 2004.
[86]
Immormino, R.M.; Kang, Y.; Chiosis, G.; Gewirth, D.T. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class hsp90 inhibitors. J. Med. Chem. 2006, 49, 4953–4960, doi:10.1021/jm060297x.
[87]
Corbett, K.D.; Berger, J.M. Structure of the atp-binding domain of plasmodium falciparum hsp90. Proteins 2010, 78, 2738–2744, doi:10.1002/prot.22799.
[88]
Wider, D.; Peli-Gulli, M.P.; Briand, P.A.; Tatu, U.; Picard, D. The complementation of yeast with human or plasmodium falciparum hsp90 confers differential inhibitor sensitivities. Mol. Biochem. Parasitol. 2009, 164, 147–152, doi:10.1016/j.molbiopara.2008.12.011.
[89]
Shahinas, D.; Liang, M.; Datti, A.; Pillai, D.R. A repurposing strategy identifies novel synergistic inhibitors of plasmodium falciparum heat shock protein 90. J. Med. Chem. 2010, 53, 3552–3557.
[90]
Ancolio, C.; Azas, N.; Mahiou, V.; Ollivier, E.; Di Giorgio, C.; Keita, A.; Timon-David, P.; Balansard, G. Antimalarial activity of extracts and alkaloids isolated from six plants used in traditional medicine in mali and sao tome. Phyto. Res. 2002, 16, 646–649, doi:10.1002/ptr.1025.
[91]
Azas, N.; Laurencin, N.; Delmas, F.; Di, G.C.; Gasquet, M.; Laget, M.; Timon-David, P. Synergistic in vitro antimalarial activity of plant extracts used as traditional herbal remedies in Mali. Par. Res. 2002, 88, 165–171.
[92]
Fiot, J.; Sanon, S.; Azas, N.; Mahiou, V.; Jansen, O.; Angenot, L.; Balansard, G.; Ollivier, E. Phytochemical and pharmacological study of roots and leaves of guiera senegalensis j.F. Gmel (combretaceae). J. Ethnopharmacol. 2006, 106, 173–178, doi:10.1016/j.jep.2005.12.030.
[93]
Traore-Keita, F.; Gasquet, M.; Di Giorgio, C.; Ollivier, E.; Delmas, F.; Keita, A.; Doumbo, O.; Balansard, G.; Timon-David, P. Antimalarial activity of four plants used in traditional medicine in mali. Phyto. Res. 2000, 14, 45–47, doi:10.1002/(SICI)1099-1573(200002)14:1<45::AID-PTR544>3.0.CO;2-C.
[94]
Shahinas, D.; Macmullin, G.; Benedict, C.; Crandall, I.; Pillai, D.R. Harmine is a potent antimalarial targeting hsp90 and synergizes with chloroquine and artemisinin. Antimicrob. Agents Chemother. 2012, 56, 4207–4213, doi:10.1128/AAC.00328-12.
[95]
Biamonte, M.A.; Van de Water, R.; Arndt, J.W.; Scannevin, R.H.; Perret, D.; Lee, W.C. Heat shock protein 90: Inhibitors in clinical trials. J. Med. Chem. 2010, 53, 3–17, doi:10.1021/jm9004708.
[96]
Berenbaum, M.C. What is synergy? Pharmaco. Rev. 1989, 41, 93–141.
[97]
Cooper, R.A.; Hartwig, C.L.; Ferdig, M.T. Pfcrt is more than the plasmodium falciparum chloroquine resistance gene: A functional and evolutionary perspective. Acta Trop. 2005, 94, 170–180, doi:10.1016/j.actatropica.2005.04.004.
[98]
Cooper, R.A.; Ferdig, M.T.; Su, X.Z.; Ursos, L.M.; Mu, J.; Nomura, T.; Fujioka, H.; Fidock, D.A.; Roepe, P.D.; Wellems, T.E. Alternative mutations at position 76 of the vacuolar transmembrane protein pfcrt are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in plasmodium falciparum. Mol. Pharmacol. 2002, 61, 35–42.
[99]
Chinappi, M.; Via, A.; Marcatili, P.; Tramontano, A. On the mechanism of chloroquine resistance in plasmodium falciparum. PloS One 2010, 5, e14064.
[100]
Johnson, D.J.; Fidock, D.A.; Mungthin, M.; Lakshmanan, V.; Sidhu, A.B.; Bray, P.G.; Ward, S.A. Evidence for a central role for pfcrt in conferring plasmodium falciparum resistance to diverse antimalarial agents. Mol. Cell 2004, 15, 867–877, doi:10.1016/j.molcel.2004.09.012.
[101]
Wellems, T.E. Transporter of a malaria catastrophe. Nat. Med. 2004, 10, 1169–1171.
[102]
Mu, J.; Myers, R.A.; Jiang, H.; Liu, S.; Ricklefs, S.; Waisberg, M.; Chotivanich, K.; Wilairatana, P.; Krudsood, S.; White, N.J.; et al. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat. Genet. 2010, 42, 268–271, doi:10.1038/ng.528.
[103]
Leeson, P.D.; St-Gallay, S.A. The influence of the 'organizational factor' on compound quality in drug discovery. Nat. Rev. Drug Discovery 2011, 10, 749–765, doi:10.1038/nrd3552.
